Human Metapneumovirus and Human Parainfluenza Infection
Conditions
Keywords
ModernaTX, mRNA-1653, human metapneumovirus, human parainfluenza, human parainfluenza vaccine, virus diseases, RNA virus infections, paramyxoviridae infections, mononegavirales infections
Brief summary
This clinical study will assess the safety and immunogenicity of 2 dose levels of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, in healthy adults (18 to 49 years of age) and 2 dose levels in children (12 to 59 months of age) with serologic evidence of prior exposure. The safety profile of the adult cohort will permit enrollment of the pediatric cohort.
Interventions
BIOLOGICALmRNA-1653
Sterile liquid for injection
BIOLOGICALPlacebo
Sterile liquid for injection
Sponsors
ModernaTX, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Observer blind
Intervention model description
Parallel for the Adult Cohort, followed by Sequential Assignment for the Pediatric Cohort
Eligibility
Sex/Gender
ALL
Age
12 Months to 49 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: * Adults 18 to 49 years of age and children 12 to 59 months of age at the time of consent who, in the opinion of the Investigator, are in good health based on review of medical history and screening physical examination * Adult participant or parent(s)/legal guardian(s) has provided written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol * Screening laboratory values Grade ≤1 Specific inclusion criteria for adults 18 to 49 years of age: * Body mass index (BMI) from ≥18 kg/m\^2 and ≤35 kg/m\^2 * Female participants must be either of non-childbearing potential or if of childbearing potential may be enrolled if the participant: 1) has a negative pregnancy test at Screening and on the day of vaccination, and 2) has practiced adequate contraception or has abstained from all activities that could lead to pregnancy for 28 days prior to vaccination, and 3) has agreed to continue adequate contraception through 3 months following the last vaccination, and 4) is not currently breastfeeding Specific inclusion criteria for children 12 to 59 months of age: * Seropositive for both hMPV and PIV3 neutralizing antibody at Screening * Has received routine immunizations appropriate for age per the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) * Current height and weight above the third percentile for age Key
Exclusion criteria
Adult and pediatric participants eligible for this study must not meet any of the following criteria: * Acutely ill or febrile (temperature ≥38.0℃/100.4°F, regardless of route) on the day of the first vaccination * Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care * Receipt of, or plans for receipt of an inactivated vaccine(s) 14 days prior to though 14 days following each study injection or a live virus vaccine(s) within 28 days prior to, or plans to through 28 days following each study injection. The exception is any COVID-19 vaccine (regardless of type of vaccine) that becomes available to the participant during the study; efforts should be made to space study vaccinations and COVID-19 vaccinations by at least 7 and preferably 14 days, but COVID-19 vaccinations should not be delayed. * Any chronic administration of an immunosuppressant or other immune modifying drug * Prior administration of investigational agent using lipid nanoparticle formulations * Donation of blood or blood products ≥450 mL within 28 days of the Screening visit (for the Adult Cohort) * Intravenous blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment * Participated in an interventional clinical trial within 28 days prior to the day of enrollment, or plans to do so while enrolled in this trial * Has a family member or household contact who is an employee of the research center or otherwise involved with the conduct of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Up to 7 days after each dose administration |
| Proportion of Participants with Unsolicited Adverse Events (AEs) | Up to 28 days after each dose administration |
| Proportion of Participants with Serious Adverse Events (SAEs) and Medically-Attended AEs | Up to 1 year after the last dose administration |
Secondary
| Measure | Time frame |
|---|---|
| Geometric mean titer (GMT) of Serum Anti-hMPV and Anti-PIV3 Neutralizing Antibodies | Day 29, 57, 85, and 224 for adults; Day 29 and 85 for pediatric participants |
| Geometric Mean Ratio (GMR) of Post-Baseline/Baseline Titers of Serum Anti-hMPV and Anti-PIV3 Neutralizing Antibodies | Day 29, 57, 85, and 224 for adults; Day 29 and 85 for pediatric participants |
| Proportion of Participants with ≥2-Fold and ≥4-Fold Increases in Serum Anti-hMPV or Anti-PIV3 Neutralizing Antibody Titer from Baseline | Day 29, 57, 85, and 224 for adults; Day 29 and 85 for pediatric participants |
Countries
United States
Outcome results
None listed